Hoʻolaha i ke kaʻina hana hoʻomohala lāʻau
ʻIke Nui
ʻO ka papa mua a me ka papa hana maikaʻi loa i hoʻolālā ʻia e hoʻoponopono i nā pono olakino nui ʻole ma o ka hoʻomohala ʻana i ka mono a me ka bi-specific protein therapeutics, antibody drug conjugates a me macrophage stimulating agents no nā maʻi ma ka honua holoʻokoʻa.
Moolelo
ʻO ka loaʻa ʻana o ka ʻenehana monoclonal antibody (mAb) e Kohler lāua ʻo Milstein i ka makahiki 1975 i hiki ke hana i nā antibodies ma ke ʻano he papa o nā lāʻau lapaʻau (Kohler & Milstein, 1975).ʻO nā antibodies monoclonal (mAbs) kekahi o nā kahua lāʻau lapaʻau i hoʻohana nui ʻia no nā maʻi maʻi a i ʻole ka lāʻau lapaʻau maʻi maʻi maʻi no ka mea koho lākou i nā pathogens, nā maʻi maʻi maʻi, nā maʻi maʻi ʻaʻai, a me nā cell immune.Ma kēia ala, hoʻokaʻawale lākou i ka hoʻopau ʻana i nā molekele a me nā cell me ka liʻiliʻi o nā hopena ʻaoʻao ma mua o nā modalities therapeutic.ʻO ka mea kūikawā, hiki i nā mAbs therapeutic cancer ke hoʻomaopopo i nā protein-surface protein ma nā cell target a laila pepehi i nā cell i hoʻopaʻa ʻia e nā mīkini he nui.
Hoʻemi nui ka hana kanaka i ka immunogenicity o ka antibody therapeutic i loko o ke kanaka, e hiki ai ke hoʻokele mau.ʻO ia mau holomua i nā ʻenehana antibody ua hopena i kahi pahū i ka hoʻomohala ʻana i nā mAbs therapeutic i nā makahiki i hala.Hoʻokumu pū ʻia a hoʻolaha ʻia kekahi ʻano o nā antibody derivatives, ʻo ia hoʻi nā protein Fc-fusion, antibody-drug conjugates (ADCs), immunocytokines (antibody-cytokine fusions), a me nā antibody-enzyme fusions.
Nā hopena lāʻau
No nā poʻe maʻi, ʻoi aku ka liʻiliʻi o nā lāʻau lapaʻau hou, ʻoi aku ka liʻiliʻi o nā hale maʻi, hoʻomaikaʻi i ka maikaʻi o ke ola, hoʻonui i ka huahana, a ʻo ka mea nui, nā ola lōʻihi.Akā, he hana lōʻihi a paʻakikī ka hoʻomohala ʻana i ka lāʻau.
Kuhikuhi
Kohler G, Milstein C. Nā moʻomeheu hoʻomau o nā pūnaewele i hoʻohui ʻia e huna ana i ka antibody o ka kikoʻī i koho mua ʻia.ʻAno.1975;256:495–497.doi: 10.1038/256495a0
Ecker DM, Jones SD, Levine HL.ʻO ka mākeke antibody monoclonal therapeutic.MAbs.2015;7:9–14.doi: 10.4161/19420862.2015.989042.
Peters C, Brown S. Antibody-drug conjugates like novel anti-cancer chemotherapeutics.Biosci Rep. 2015;35(4):e00225.Paʻi ʻia 2015 Iulai 14. Loaʻa ma https://pubmed.ncbi.nlm.nih.gov/26182432/.Loaʻa iā Iulai 2020.
Reichert, JM, a me Valge-Archer, VE (2007).Nā ʻano hoʻomohala no nā lāʻau lapaʻau monoclonal antibody cancer.Nat Rev Drug Discov 6, 349–356.
Lazar, GA, Dang, W., Karki, S., Vafa, O., Peng, JS, Hyun, L., Chan, C., Chung, HS, Eivazi, A., Yoder, SC, a me al.(2006).ʻO nā ʻano ʻokoʻa Fc antibody i hana ʻia me ka hana effector i hoʻonui ʻia.PNAS 103, 4005–4010.
ʻenehana loea loea i hoʻolaʻa ʻia e alakaʻi iā ʻoe
E like me kāu mau pono maoli, e koho i nā kaʻina hana hoʻolālā holoʻokoʻa kūpono loa